XML 18 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Non- Controlling Interest
Beginning Balances (in shares) at Dec. 31, 2017   85,598        
Beginning Balances at Dec. 31, 2017 $ 187,900 $ 856 $ 682,809 $ (495,479) $ (286) $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   1,922        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 13,696 $ 18 13,678      
Issuance of common stock under employee stock purchase plan (in shares)   163        
Issuance of common stock under employee stock purchase plan 690 $ 2 688      
Issuance of common stock under public offering, net of issuance costs (in shares)   14,157        
Issuance of common stock under public offering, net of issuance costs 215,757 $ 142 215,615      
Stock-based compensation 10,374   10,374      
Net unrealized gain (loss) on marketable securities 42       42  
Net loss (49,670)     (49,670)    
Ending Balances (in shares) at Sep. 30, 2018   101,840        
Ending Balances at Sep. 30, 2018 379,906 $ 1,018 923,164 (544,032) (244) 0
Beginning Balances (in shares) at Jun. 30, 2018   101,624        
Beginning Balances at Jun. 30, 2018 387,867 $ 1,016 918,197 (531,189) (157) 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   216        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 1,159 $ 2 1,157      
Stock-based compensation 3,810   3,810      
Net unrealized gain (loss) on marketable securities (87)       (87)  
Net loss (12,843)     (12,843)   0
Ending Balances (in shares) at Sep. 30, 2018   101,840        
Ending Balances at Sep. 30, 2018 379,906 $ 1,018 923,164 (544,032) (244) 0
Beginning Balances (in shares) at Dec. 31, 2018   102,188        
Beginning Balances at Dec. 31, 2018 367,257 $ 1,022 929,632 (562,696) (1,440) 739
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   800        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 3,363 $ 8 3,355      
Issuance of common stock under employee stock purchase plan (in shares)   132        
Issuance of common stock under employee stock purchase plan 1,139 $ 1 1,138      
Issuance of common stock under public offering, net of issuance costs (in shares)   12,650        
Issuance of common stock under public offering, net of issuance costs 136,308 $ 127 136,181      
Stock-based compensation 14,091   14,091      
Acquisition of additional shares of Sangamo France/TxCell (321)         (321)
Issuance costs related to Sangamo France/TxCell Acquisition (25)   (25)      
Foreign currency translation adjustment (4,139)       (4,139)  
Net unrealized gain (loss) on marketable securities 678       678  
Net loss (99,920)     (99,741)   (179)
Ending Balances (in shares) at Sep. 30, 2019   115,770        
Ending Balances at Sep. 30, 2019 419,328 $ 1,158 1,084,372 (661,540) (4,901) 239
Beginning Balances (in shares) at Jun. 30, 2019   115,603        
Beginning Balances at Jun. 30, 2019 445,748 $ 1,156 1,078,976 (634,233) (765) 614
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)   167        
Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax 704 $ 2 702      
Stock-based compensation 4,701   4,701      
Acquisition of additional shares of Sangamo France/TxCell (321)         (321)
Issuance costs related to Sangamo France/TxCell Acquisition (7)   (7)      
Foreign currency translation adjustment (4,077)       (4,077)  
Net unrealized gain (loss) on marketable securities (59)       (59)  
Net loss (27,361)     (27,307)   (54)
Ending Balances (in shares) at Sep. 30, 2019   115,770        
Ending Balances at Sep. 30, 2019 $ 419,328 $ 1,158 $ 1,084,372 $ (661,540) $ (4,901) $ 239